UPDATE: JP Morgan Upgrades Biogen Seeing Upside to Shares

In a report published Thursday, JP Morgan analyst Geoff Meacham upgraded
Biogen Idec Inc.BIIB
from Neutral to Overweight and raised the price target from $300.00 to $375.00. Meacham emphasized that Biogen's pipeline opportunities and MS survey implies an upside to shares. The analyst commented, “With respect to the MS franchise, we conducted a survey of 50 neurologists that points to upside for Tecfidera. Indeed, we have also fine tuned our MS estimates and are above consensus for Tecfidera, which is the key near-term commercial driver.” Shares of Biogen Idec closed at $308.81. The stock is currently up 2 percent in Thursday's premarket trading.
Loading...
Loading...
BIIB Logo
BIIBBiogen Inc
$133.07-1.79%

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score
Edge Rankings
Momentum
16.91
Growth
41.38
Quality
26.58
Value
28.57
Price Trend
Short
Medium
Long
Market News and Data brought to you by Benzinga APIs
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm

Comments
Loading...